AriBio gets exclusive marketing rights in China for Alzheimer’s candidate AR1001 in $770m deal
In a significant stride towards addressing early Alzheimer’s disease, AriBio Co., Ltd. (AriBio) has announced an exclusive agreement to market AR1001, a pioneering investigational drug, in China. The deal, potentially worth up to $770 million USD, marks a critical milestone in the global fight against Alzheimer’s disease, particularly targeting the growing patient population in China. […]